Lakefront Biotherapeutics - American Depositary Shares (LKFT) Stock Price, News, Quote & History

Gilead Sciences (GILD) stock rose 24% YTD, outperforming the S&P 500. Its forward P/E is 15.5, based on normalized earnings. Q2 2026 revenue grew 10% to $7.8B, with HIV sales up 12%. Gilead gained FDA approvals for Yeztugo and Hepcludex, adding growth drivers.

Global healthcare companies, including Pfizer, Eli Lilly, and AstraZeneca, are investing billions in US manufacturing and research. Pfizer plans $70B, Eli Lilly $27B, and AstraZeneca $50B. Investments aim to mitigate supply-chain risks and tariff impacts, with some companies reporting minimal 2025 tariff effects.

Nurix Therapeutics (NRIX) and Gilead Sciences extended their oncology research collaboration by two years. Nurix will receive a $10M extension fee and could earn up to $1.3B in milestones. Nurix retains co-development and 50/50 profit-sharing options for up to two programs in the U.S.

A study found that 90% of hepatitis D patients who were undetectable for 96 weeks before stopping bulevirtide remained undetectable for 2 years off therapy. Bulevirtide, approved in several countries, is the first treatment for hepatitis D. The study, sponsored by Gilead Sciences, suggests that stopping the drug can lead to relapses and liver enzyme flares, particularly in patients with cirrhosis.

Gilead Sciences (GILD) expanded its royalty-free licensing for lenacapavir to include a once-yearly HIV PrEP formulation, covering 120 lower-income countries. The move aims to accelerate manufacturing and secure market dominance. Gilead's HIV sales grew 12% YoY to $5.7B in Q2 2026, but the company reported losses due to acquisition-related R&D charges.

Gilead Sciences expanded licensing for investigational once-yearly lenacapavir for HIV prevention, aiming to streamline future approval and distribution. WHO updated malaria guidelines to include Coartem® Baby, an antimalarial for newborns developed by Novartis and partners, now approved in 11 countries.